NVV1:FRA
Novavax Inc
6,80 €
arrow_downward
-3,95%(-0,28) 1K
23-iyl, 22:00:00 (GMT+2) · EUR
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoNVV1 tikeri uchun statistika yaratilmoqda...
Ochish
6,96 €
Yuqori
6,96 €
Past
6,80 €
Bozor kapitali
1,29Â mlrd
Oʻrtacha hajm
2,91Â ming
Hajmi
400,00
52 haftalik eng yuqori
10,03 €
52 haftalik eng past
5,41 €
Xodimlar soni
749
Ochish
6,96 €
Yuqori
6,96 €
Past
6,80 €
Bozor kapitali
1,29Â mlrd
Oʻrtacha hajm
2,91Â ming
Hajmi
400,00
52 haftalik eng yuqori
10,03 €
52 haftalik eng past
5,41 €
Xodimlar soni
749
Yangiliklar
Internetdagi manbalardan
Ad-hoc-news.de
·
3 kun oldin
NVAX stock trades in a wide range as Novavax works through Covid vaccine transition
https://www.dars.gov.et/
·
1 hafta oldin
Novavax (NVAX) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Operational Progress - Guidance Accuracy Score
Profil
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Novavax Inc haqida
CEOJohn C. Jacobs
Xodimlar soni749
Asos solingan1987
Bosh ofislarGaithersburg, Maryland, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytnovavax.com
AI kontentda xatolar boʻlishi mumkin. Batafsil